Culleton Bruce 4

What Happened
Bruce Culleton, CEO of ProKidney Corp. (PROK), was granted a derivative award of 3,000,000 shares on March 1, 2026. The filing reports an acquisition at $0.00 (total reported value $0). The award is described in the filing footnote as an option with a multi-year vesting schedule.

Key Details

• Transaction date: March 1, 2026. Form 4 filed March 3, 2026 (timely filing).
• Transaction type/code: A — Grant, award or other acquisition (derivative).
• Shares awarded: 3,000,000 shares; reported acquisition price $0.00 (reported value $0).
• Vesting: Footnote states the option vests in substantially equal monthly installments over four years beginning March 1, 2026.
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Filing accession: 0001193125-26-086724.

Context
This was a grant of a derivative equity award (the filing footnote calls it an option) rather than an open-market purchase or sale. Because it vests over four years, the economic benefit to the insider depends on future vesting and any exercise price or future sale; no immediate sale or cashless exercise is indicated. Grants like this are common for executive compensation and are informational rather than a direct buy/sell signal.